Aeterna Zentaris (AEZS) - רווח נקי למניה (EPS TTM)

High-margin licensing royalties stabilize the cash flow of Aeterna Zentaris (AEZS), while R&D activity is currently restrained and strictly regulated. The current EPS TTM reflects equity income dynamics, where the value -2.31 represents the current metric. Meanwhile, the production of orphan drugs relies on automated conveyor systems that minimize personnel involvement in packaging.

This indicator reflects operational efficiency by excluding the impact of one-time accounting adjustments on the final financial result. The metric measures the portion of net profit attributable to a single common share per year. For the specialty pharmaceutical company Aeterna Zentaris (AEZS), such profit stability confirms the defensive qualities of the business. Regulatory risks carry more weight here than market cycles. The 12-month net profit per share trend for Aeterna Zentaris (AEZS) helps identify changes in profitability in a timely manner.